Division of Cardiovascular Medicine, University of California San Diego, San Diego, California.
Division of Cardiovascular Medicine, University of California San Diego, San Diego, California.
Heart Rhythm. 2022 Jul;19(7):1158-1164. doi: 10.1016/j.hrthm.2022.02.031. Epub 2022 Mar 4.
Data on lead management in patients with congenital complete heart block (CCHB) with cardiac implantable electronic devices are lacking.
The purpose of this study was to describe the natural history and outcomes in patients with CCHB with cardiac implantable electronic devices undergoing transvenous lead extraction (TLE).
Data on all attempted TLE procedures in patients with CCHB at 2 institutions between 2011 and 2021 were collected from a retrospective registry.
Overall, 16 patients (mean age at transvenous device implant 13.8 ± 4.7 years) were included. Before TLE, patients underwent an average of 2.25 ± 1.3 generator changes, 3 (19%) underwent cardiac resynchronization therapy upgrade, and 7 (44%) underwent a lead revision with subsequently abandoned leads. Mean patient age at TLE was 34.4 ± 9.4 years with a mean duration of lead implant of 19.2 ± 6.9 years. Lead malfunction (n = 11 [69%]) and infection (n = 5 [31%]) were the most common indications for TLE. A total of 38 leads were removed, with complete procedural success achieved in 14 of 16 (87.5%). Two (12.5%) major complications occurred, including right ventricular laceration and superior vena cava tear requiring sternotomies. All patients survived at 1-year follow-up.
Patients with CCHB represent a unique cohort highlighted by several generator changes, lead revisions, and abandoned leads at a young age, along with a long duration of lead dwelling time and a high prevalence of lead malfunction requiring TLE. There may be a high risk of major complications during TLE, suggesting TLE should be performed only in experienced centers. Larger studies are needed to confirm these findings.
先天性完全性心脏传导阻滞(CCHB)伴心脏植入式电子设备患者的铅管理数据缺乏。
本研究旨在描述 2 家机构在 2011 年至 2021 年间接受经静脉导线拔除术(TLE)的 CCHB 伴心脏植入式电子设备患者的自然病史和结局。
从回顾性登记处收集了 2 家机构在 2011 年至 2021 年间所有尝试进行 CCHB 患者 TLE 手术的数据。
共有 16 名患者(经静脉设备植入时的平均年龄为 13.8 ± 4.7 岁)入选。在 TLE 之前,患者平均经历了 2.25 ± 1.3 次发电机更换,3 例(19%)进行了心脏再同步治疗升级,7 例(44%)进行了导线修订,并随后废弃了导线。TLE 时患者的平均年龄为 34.4 ± 9.4 岁,导线植入的平均时间为 19.2 ± 6.9 年。导线故障(n = 11 [69%])和感染(n = 5 [31%])是 TLE 最常见的指征。共取出 38 根导线,16 例患者中的 14 例(87.5%)达到完全手术成功。发生 2 例(12.5%)严重并发症,包括右心室撕裂和需要开胸的上腔静脉撕裂。所有患者在 1 年随访时均存活。
CCHB 患者是一个独特的群体,其特点是在年轻时经历了多次发电机更换、导线修订和废弃导线,导线留置时间长,导线故障导致需要 TLE 的比例高。TLE 过程中可能存在严重并发症的高风险,因此 TLE 应仅在有经验的中心进行。需要更大规模的研究来证实这些发现。